Labcorp to open new kit production innovation base in Suzhou, China

In late July, Labcorp joined the signing ceremony of its kit production innovation base project in Suzhou New District, China. The event was held and organized by the Suzhou New District government and saw attendance from city leadership officials, including Deputy Mayor of Suzhou city, Mr. Xiaodong Tang.

The Kit Production Innovation Base project aims to shorten the lead time of kit supplies to Chinese investigator sites, strengthening the support of clinical trials in China and other countries in the Asia-Pacific region. It will be Labcorp’s third kit production site in the world, joining existing facilities in Indianapolis (USA) and Mechelen (Belgium) in producing industry-leading specimen collection kits for clinical trials.

“We have a long operating history in China, opening our first facility in Beijing in 1998 with subsequent facilities in Shanghai, Dalian and Guangzhou. We are excited to expand our footprint in Suzhou New District. The addition of a new kit fulfillment facility will lead to shorter lead times allowing us to better serve and meet the needs of our local clients. We anticipate the facility to be operational in the first half of 2023, coinciding with our 25th anniversary of the opening of the Beijing facility. This signifies our confidence in new drug development business in China.”

Dr. Paul Kirchgraber
Executive Vice President and Chief Executive Officer
Labcorp Drug Development

“Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services. Our footprint in the Asia-Pacific region has covered 6 countries with more than 3000 employees. We continue extending our footprint in China by investing in this new facility in Suzhou, which will further enhance the speed of clinical trial testing service.””

Dr. Honggang Bi
Former SVP and Head of Asia Pacific Region
Labcorp